Le Lézard
Classified in: Health
Subjects: MAV, DIS, DEI

/R E P E A T -- Press conference - The scandal repeats itself and it's worse than ever: Mammograms are still denied to women with disabilities/


Press conference
Intercontinental Hotel
360 St-Antoine Street West, Sherwood room
Montréal (Québec)
H2Y 3X4 
May 4, 2022 10.00 am

MONTREAL, May 3, 2022 /CNW Telbec/ - RAPLIQ invites you to a press conference at the above-mentioned address.

For a third time, we have conducted a study on the accessibility of designated screening centers (DSC).

Results are worse than ever !

In 2017, to follow up on the file, we redid the exercise by calling the 97 clinics registered on the site of the designated screening centers (DSC) of the Quebec breast cancer screening program (QBSCP).

We were bitterly disappointed to find that not only were access to mammography examinations still being refused to women in wheelchairs, but that this refusal was also falsely justified. Falsehoods such as: "the devices (mammographs) do not lower"; "you absolutely must transfer to a small stool", etc.

We are still getting humiliating remarks such as: "You really can't stand up at all at all? - "You must be able to stand" - "No, in your case, it's the hospital."

Documents will be included in the press kits to support our statement.

About RAPLIQ:

RAPLIQ is a pan-Quebec organization that supports and accompanies people with disabilities who are victims of discrimination to defend and claim their rights and to promote them by aiming to eradicate this discrimination too often made against them.

SOURCE RAPLIQ (Regroupement des activistes pour l'inclusion au Québec)


These press releases may also interest you

at 10:05
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered...

at 10:05
Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I...

at 10:05
AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held...

at 10:05
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting...

at 10:05
After more than 60 years of researching the power of plants in Germany, Bayer Consumer Health is introducing Iberogasttm, a plant-based digestive relief product, to the United States. Formulated with a clinically proven, proprietary six-herb blend,...

at 10:05
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab ("BOT/BAL") in patients with...



News published on and distributed by: